Suzanne Vang, PhD is a T32 Postdoctoral Fellow in the Department of Population Health Science and Policy at the Icahn School of Medicine at Mount Sinai. Her research focuses on investigating and addressing cancer screening disparities in medically underserved populations, particularly in Asian Pacific Islanders, Latinas, and African Americans. Dr. Vang has recently been awarded a Postdoctoral Fellowship from the American Cancer Society to develop and pilot test culturally- and linguistically-tailored decision aids to improve breast density care for Latina women with high breast density. She received her Ph.D. in October 2017 from Columbia University.
Deborah Marshall, MD, MSCR is a chief resident in Radiation Oncology and a T32 and Holman Pathway research fellow at the Icahn School of Medicine at Mount Sinai. After graduating from the University of California, Berkeley with a degree in comparative ethnic studies and working in immigration law, Dr. Marshall pursued her medical training and a Master's degree in clinical research at the University of California, San Diego School of Medicine. She then completed her transitional year internship at Memorial Sloan Kettering Cancer Center. As a research fellow, she now leads a multidisciplinary team studying female sexual toxicity after pelvic radiotherapy supported by grants from the Patty Brisben Foundation, NRG Oncology, and the Conquer Cancer Foundation of ASCO. Her clinical scientific research focuses on clinical and population-based radiation toxicity outcomes in priority populations including women and persons with HIV. Her social scientific research focuses on financial conflicts of interest in medicine and health policy.
Stacyann Bailey, PhD is a T32 Fellow in Cancer Prevention and Control at Mount Sinai. She earned her doctoral degree in biomedical engineering from Rensselaer Polytechnic Institute and completed her undergraduate studies at the City College of New York. Dr. Bailey is trained in the assessment of bone matrix quality and mechanical properties, which degrades with aging and diseases. She is currently investigating the clinical and pathological characteristics associated with knowledge and perceived risk of osteoporosis and adherence to behaviors that promote bone health in older Breast Cancer patients. Her research interest lies in the development of new strategies to predict, manage, and mitigate pathological fractures in cancer patients.
Amanda Leiter MD, MS is a clinical faculty member and research fellow in the Division of Endocrinology, Diabetes, and Bone Disease as well as a new fellow with DGIM’s Cancer Prevention and Control Fellowship. She received her MD and MS in Clinical Research from the Icahn School of Medicine at Mount Sinai. Then she completed an internal medicine residency and clinical endocrinology fellowship at Mount Sinai Hospital. Her research interests relate to the intersection of metabolic disease and cancer-- how metabolic disease impacts cancer outcomes, and vice versa, how cancer diagnosis and treatments impact metabolic diseases.
Melissa Mazor, RN, MS, PhD is an Instructor and T32 Cancer Prevention and Control Fellow in the Mount Sinai Division of General Internal Medicine. Prior to joining the faculty at Mount Sinai, Melissa was a postdoctoral fellow at NYU and the VA Quality Scholar Program in the UCSF Division of Geriatrics. Melissa received her PhD and MS in nursing from University of California, San Francisco and BA in psychology from the University of California, Berkeley. Her research investigates cancer survivorship outcomes in vulnerable populations. She is particularly interested in developing and implementing culturally sensitive, community-based interventions to mitigate distress, symptom burden, and survivorship outcomes in underserved Black, Latinx, and Asian American cancer survivors. Melissa is the principal investigator of a qualitative study examining distress and symptom burden in Black female cancer survivors. She is also the project lead for the ‘Environmental Scan for Mental Health Screening for Asian American Cancer Survivors’ at New York University funded through the Cancer Prevention and Control Research Network.